1. Home
  2. Browse
  3. HRA007180
HRA007180
   HRA007180.xlsx
Title:
single cell RNAseq data of patients with ovarian cancer
Release date:
2025-05-01
Description:
Ovarian cancer is a serious gynecological malignancy that poses a significant threat to women's life and health, and China has the highest number of patients worldwide. Ovarian cancer is difficult to diagnose early due to lacking symptoms, difficult to classify due to complex types, and difficult to treat due to drug resistance and recurrent. As a result, the 5-year overall survival rate has remained between 30% ~ 40% for over a century. It severely impedes the accomplishment of the arduous task proposed by President Xi that increasing the 5-year survival rate of cancer by 15%, as outlined in the "Healthy China 2030 Plan". Based on the clinic trial NeoAdjuvant Niraparib Therapy (NANT, identifier: NCT04507841), here we investigate the effects of genetic background, tumor microenvironment and their interactions on PARP inhibitor resistance of ovarian cancer through multi omics sequencing.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA016620
Study type:
Disease Study
Disease name:
ovarian cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC000642
DAC name:
Qinglei Gao
Contact person:
Gao Qinglei
Email:
qingleigao@hotmail.com
Description:
Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, Hubei, China
Individuals & samples
Files
Request Data
Submitter:   Gao Qinglei / qingleigao@hotmail.com
Organization:   Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Submission date:   2024-04-15
Requests:   5